Hongqin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hongqin Zhang has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ailing Zhong
Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong’an Road, Xuhui District, Shanghai 200032, China
1 shared publication - Lin Guo
Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China
1 shared publication - Renquan Lu
Department of Clinical Laboratory Fudan University Shanghai Cancer Center Shanghai China
1 shared publication - Tianqing Yan
Department of Clinical Laboratory, Shanghai Cancer Center, Fudan University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 1 September 2022
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 44 (9) , 3948-3958
COPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer
Development of platinum resistance is one of the major causes of epithelial ovarian cancer (EOC) treatment failure. COP9 signalosome subunit 5 (COPS5) was found to take part in the progression of EOC in our previous study. Herein, we aim to uncover the potential utility of COPS5 in EOC chemoresistance. COPS5 levels were analyzed to define clinic pathologic correlates using a matched tissue microarray and online datasets. The effect of COPS5 inhibition by the lentivirus-mediated short hairpin RNA on cell viability, proliferation and migration was accessed in vitro and in vivo. Results showed that COPS5 was upregulated in patients after platinum resistance. Kaplan–Meier survival curves revealed that COPS5 overexpression was correlated with shorter PFS and OS. COPS5 downregulation inhibited the cell proliferation, migration, and reduced the sensitivity of EOC to platinum. Overall, our data indicated that COPS5 inhibition might represent a new therapeutic strategy for overcoming platinum resistance in patients with EOC.
- 1 September 2022
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 44 (9) , 3948-3958
Open AccessCOPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer
Development of platinum resistance is one of the major causes of epithelial ovarian cancer (EOC) treatment failure. COP9 signalosome subunit 5 (COPS5) was found to take part in the progression of EOC in our previous study. Herein, we aim to uncover the potential utility of COPS5 in EOC chemoresistance. COPS5 levels were analyzed to define clinic pathologic correlates using a matched tissue microarray and online datasets. The effect of COPS5 inhibition by the lentivirus-mediated short hairpin RNA on cell viability, proliferation and migration was accessed in vitro and in vivo. Results showed that COPS5 was upregulated in patients after platinum resistance. Kaplan–Meier survival curves revealed that COPS5 overexpression was correlated with shorter PFS and OS. COPS5 downregulation inhibited the cell proliferation, migration, and reduced the sensitivity of EOC to platinum. Overall, our data indicated that COPS5 inhibition might represent a new therapeutic strategy for overcoming platinum resistance in patients with EOC.